Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) CEO Daniel Patrick O'day sold 15,000 shares of the stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $130.31, for a total value of $1,954,650.00. Following the completion of the transaction, the chief executive officer directly owned 592,133 shares of the company's stock, valued at approximately $77,160,851.23. This represents a 2.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Daniel Patrick O'day also recently made the following trade(s):
- On Wednesday, July 1st, Daniel Patrick O'day sold 15,000 shares of Gilead Sciences stock. The stock was sold at an average price of $126.29, for a total transaction of $1,894,350.00.
- On Monday, June 1st, Daniel Patrick O'day sold 15,000 shares of Gilead Sciences stock. The stock was sold at an average price of $131.46, for a total transaction of $1,971,900.00.
Gilead Sciences Stock Performance
NASDAQ:GILD opened at $135.25 on Wednesday. The company has a market cap of $167.92 billion, a P/E ratio of 18.43 and a beta of 0.32. Gilead Sciences, Inc. has a twelve month low of $108.46 and a twelve month high of $157.29. The company's 50-day moving average price is $129.58 and its 200-day moving average price is $136.11. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($7.26) by $0.51. The company had revenue of $7.80 billion during the quarter, compared to analysts' expectations of $7.40 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. Gilead Sciences's revenue was up 10.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.01 EPS. On average, sell-side analysts forecast that Gilead Sciences, Inc. will post -0.78 earnings per share for the current fiscal year.
Gilead Sciences Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be given a $0.82 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.4%. Gilead Sciences's dividend payout ratio is 44.69%.
Key Stories Impacting Gilead Sciences
Here are the key news stories impacting Gilead Sciences this week:
- Positive Sentiment: Gilead reported a second-quarter loss of $6.75 per share, narrower than analyst estimates for a loss of roughly $7.07–$7.26. Revenue increased 10.6% year over year, while product sales rose 8% and exceeded Wall Street expectations. Gilead Sciences Reports Q2 Loss, Beats Revenue Estimates
- Positive Sentiment: HIV medicines generated double-digit sales growth, reinforcing the HIV franchise as Gilead’s main growth engine. Yeztugo, the company’s HIV pre-exposure prophylaxis drug, narrowly beat sales expectations and could provide additional longer-term growth. Gilead's High-Profile HIV Drug Beat
- Positive Sentiment: Gilead prevailed in a California Supreme Court case concerning whether drugmakers have a duty to develop potentially safer alternatives to existing safe medicines. The ruling reduces a potential product-liability risk for the company. California Court Rules for Gilead
- Neutral Sentiment: Management’s fiscal 2026 EPS guidance of a $0.65–$0.30 loss is better than the consensus estimate for a $0.79 loss, but revenue guidance of $30.1 billion–$30.4 billion is slightly below the $30.5 billion analyst forecast. The outlook reflects the impact of acquisition-related costs and research-and-development spending.
- Negative Sentiment: Gilead lowered its full-year Veklury outlook after sales of the COVID-19 treatment plunged 81% in the quarter, highlighting continued pressure on a declining product. Gilead Swings to Loss on R&D Costs
- Negative Sentiment: The quarterly loss compares with $2.01 in earnings per share a year earlier, with acquisition and R&D costs weighing heavily on profitability. Gilead Second-Quarter Sales Rise
- Negative Sentiment: CEO Daniel O’Day sold 15,000 shares under a pre-arranged Rule 10b5-1 trading plan. Because the sale was planned and he retained more than 592,000 shares, it is a limited negative signal but may attract investor attention.
Analysts Set New Price Targets
A number of equities analysts have weighed in on the company. Citigroup boosted their price objective on Gilead Sciences from $156.00 to $165.00 and gave the stock a "buy" rating in a research note on Monday, April 13th. Maxim Group upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $165.00 price target on the stock in a report on Wednesday, May 20th. Rothschild & Co Redburn dropped their price objective on shares of Gilead Sciences from $170.00 to $167.00 in a report on Monday, May 11th. Leerink Partners cut shares of Gilead Sciences from an "outperform" rating to a "market perform" rating and cut their price objective for the stock from $146.00 to $127.00 in a research report on Tuesday, July 21st. Finally, Royal Bank Of Canada reduced their target price on shares of Gilead Sciences from $122.00 to $120.00 and set a "sector perform" rating on the stock in a research note on Tuesday, July 7th. Twenty-five research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of "Moderate Buy" and a consensus price target of $157.93.
Check Out Our Latest Analysis on GILD
Institutional Trading of Gilead Sciences
Hedge funds and other institutional investors have recently modified their holdings of the business. Strategic Investment Solutions Inc. IL acquired a new position in Gilead Sciences in the fourth quarter valued at about $25,000. Vermillion & White Wealth Management Group LLC increased its position in shares of Gilead Sciences by 71.4% during the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 85 shares during the last quarter. Quattro Advisors LLC purchased a new stake in shares of Gilead Sciences in the 4th quarter valued at approximately $26,000. Wealth Preservation Advisors LLC lifted its holdings in shares of Gilead Sciences by 60.0% in the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 81 shares during the last quarter. Finally, Ares Financial Consulting LLC acquired a new position in shares of Gilead Sciences in the 4th quarter worth approximately $28,000. 83.67% of the stock is owned by institutional investors and hedge funds.
About Gilead Sciences
(
Get Free Report)
Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.
Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
